Literature DB >> 11435917

Orexin-a activates phospholipase C- and protein kinase C-mediated Ca2+ signaling in dopamine neurons of the ventral tegmental area.

K Uramura1, H Funahashi, S Muroya, S Shioda, M Takigawa, T Yada.   

Abstract

The orexin-orexin receptor system has been implicated in the regulation of wakefulness/sleep states. Behavioral and psycho-stimulant effects of orexins have also been shown. Mesolimbic dopamine neurons in the ventral tegmental area (VTA) are implicated in the regulation of reward and wakefulness/sleep, In the present study, we examined the effect of orexin-A on cytosolic [Ca2+]i concentration ([Ca2+]) in the isolated rat VTA dopamine neurons. Orexin-A (10-12-10-8 M) concentration dependently increased [Ca2+]i in dopamine-containing neurons. The [Ca2+]i responses to orexin-A were inhibited under Ca2+-free conditions and by blockers of voltage-gated L- and N-type [Ca2+]i channels, nitrendipine and omega-conotoxin, respectively. The [Ca2+]i responses were also abolished by a phosphatidylcholine-specific phospholipase C inhibitor, D609, and a protein kinase C (PKC) inhibitor, calphostin C. A PKC activator, TPA, mimicked orexin-A in increasing [Ca2+]i. These results indicate that orexin-A increases [Ca2+]i in VTA dopamine neurons via phosphatidylcholine-specific PLC- and PKC-mediated activation of L- and N-type Ca2+ channels. This effect may serve as the mechanism by which orexin regulates wakefulness/sleep states and exerts its behavioral and psychostimulant effects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11435917     DOI: 10.1097/00001756-200107030-00024

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  25 in total

Review 1.  Common cellular and molecular mechanisms in obesity and drug addiction.

Authors:  Paul J Kenny
Journal:  Nat Rev Neurosci       Date:  2011-10-20       Impact factor: 34.870

2.  The wake-promoting peptide orexin-B inhibits glutamatergic transmission to dorsal raphe nucleus serotonin neurons through retrograde endocannabinoid signaling.

Authors:  Samir Haj-Dahmane; Roh-Yu Shen
Journal:  J Neurosci       Date:  2005-01-26       Impact factor: 6.167

3.  Identification of wake-active dopaminergic neurons in the ventral periaqueductal gray matter.

Authors:  Jun Lu; Thomas C Jhou; Clifford B Saper
Journal:  J Neurosci       Date:  2006-01-04       Impact factor: 6.167

4.  Orexin/hypocretin receptor signalling: a functional perspective.

Authors:  C S Leonard; J P Kukkonen
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

5.  Orexin A-induced extracellular calcium influx in prefrontal cortex neurons involves L-type calcium channels.

Authors:  J X Xia; S Y Fan; J Yan; F Chen; Y Li; Z P Yu; Z A Hu
Journal:  J Physiol Biochem       Date:  2009-06       Impact factor: 4.158

Review 6.  Hypocretins and the neurobiology of sleep-wake mechanisms.

Authors:  Luis de Lecea
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

7.  Calcium affects OX1 orexin (hypocretin) receptor responses by modifying both orexin binding and the signal transduction machinery.

Authors:  Jaana Putula; Tero Pihlajamaa; Jyrki P Kukkonen
Journal:  Br J Pharmacol       Date:  2014-11-05       Impact factor: 8.739

Review 8.  The hypocretin/orexin system: implications for drug reward and relapse.

Authors:  Ainhoa Plaza-Zabala; Rafael Maldonado; Fernando Berrendero
Journal:  Mol Neurobiol       Date:  2012-03-20       Impact factor: 5.590

Review 9.  Role of orexin receptors in obesity: from cellular to behavioral evidence.

Authors:  C E Perez-Leighton; T A Butterick-Peterson; C J Billington; C M Kotz
Journal:  Int J Obes (Lond)       Date:  2012-03-06       Impact factor: 5.095

10.  Dual orexin actions on dorsal raphe and laterodorsal tegmentum neurons: noisy cation current activation and selective enhancement of Ca2+ transients mediated by L-type calcium channels.

Authors:  K A Kohlmeier; S Watanabe; C J Tyler; S Burlet; C S Leonard
Journal:  J Neurophysiol       Date:  2008-07-30       Impact factor: 2.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.